21:28 , Dec 15, 2017 |  BioCentury  |  Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an...
20:51 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

On Dec. 14, immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million,...
11:57 , Dec 14, 2017 |  BC Extra  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, OrbiMed

Immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while Kyn disclosed...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

RaQualia gastrointestinal news

CJ Group (Seoul, South Korea) has exclusive rights to RaQualia's RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia under a 2011 deal. In 2010, RaQualia granted CJ Group's CJ CheilJedang Co. affiliate exclusive rights...
07:00 , Apr 30, 2012 |  BioCentury  |  Emerging Company Profile

Ariel: Antagonizing pain

Although standard of care treatments raise safety concerns, along with high rates of non-responders, the pipeline for acute pain continues to be short on novel targets. Ariel Pharmaceuticals Inc. is developing an in-licensed PTGER4 antagonist...